Effect of Sarcopenia and Body Shape on Cardiovascular Disease According to Obesity Phenotypes

• Published in: Diabetes & metabolism journal Vol. 45; no. 2; pp. 209 - 218
• Main Authors: Cho, Hyun-Woong, Chung, Wankyo, Moon, Shinje, Ryu, Ohk-Hyun, Kim, Min Kyung, Kang, Jun Goo
• Format: Journal Article
• Language: English
• Published: Korea (South) Korean Diabetes Association / Daehan Dangnyobyeong Hakoe 01.03.2021; Korean Diabetes Association; 대한당뇨병학회
• Subjects: Angina pectoris; Body composition; Body mass index; body size; Cardiovascular disease; Cardiovascular Diseases - epidemiology; Female; Genotype & phenotype; Glucose; Health care; High density lipoprotein; Humans; Male; Metabolic Syndrome; Metabolism; Nutrition Surveys; Obesity; Obesity - epidemiology; Obesity, Metabolically Benign; Original; Overweight; Phenotype; Questionnaires; Regression analysis; Review boards; Risk Factors; Sarcopenia; Sarcopenia - epidemiology; Somatotypes; Tomography; 내과학; United States > US; Obesity, metabolically benign; Sarcopenia; Body size
• ISSN: 2233-6079; 2233-6087; 2233-6087
• DOI: 10.4093/dmj.2019.0223

This study aimed to assess the effects of sarcopenia and A Body Shape Index (ABSI) on cardiovascular disease (CVD) risk according to obesity phenotypes. We used data from the National Health and Nutrition Examination Survey 1999 to 2012. A total of 25,270 adults were included and classified into the following groups: metabolically healthy normal weight (MHNW), metabolically healthy overweight/obese (MHO), metabolically unhealthy normal weight (MUNW), and metabolically unhealthy overweight/obese (MUO). Sarcopenia was defined as the appendicular skeletal mass index <7 kg/m2 in men and <5.5kg/m2 in women. A multivariate logistic regression analysis was performed to evaluate the odds ratio (OR) of sarcopenia and ABSI for CVD events according to the obesity phenotype. The MHNW participants with sarcopenia had higher risk for CVD than those without sarcopenia (OR, 2.69; 95% confidence interval [CI], 1.56 to 4.64). In the analysis with MHNW participants without sarcopenia as a reference, the participants with sarcopenia showed a higher OR for CVD than those without sarcopenia in both MHO (OR in participants without sarcopenia, 3.31; 95% CI, 1.94 to 5.64) (OR in participants with sarcopenia, 8.59; 95% CI, 2.63 to 28.04) and MUO participants (OR in participants without sarcopenia, 5.11; 95% CI, 3.21 to 8.15) (OR in participants with sarcopenia, 8.12; 95% CI, 4.04 to 16.32). Participants within the second and third tertiles of ABSI had higher ORs for CVDs than the counterpart of obesity phenotypes within the first tertile. These results suggest that clinical approaches that consider muscle and body shape are required.